116 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
38
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Abbvie
48
Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries.
Abbvie
2
Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8.
Abbvie
3
Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.
Abbvie
11
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
Abbvie
5
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.
Abbvie
18
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Abbvie
32
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
Abbvie
22
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.
Abbvie
16
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
Abbvie
2
Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.
Abbvie
45
Validation, Key Pharmacophores, and X-ray Cocrystal Structures of Novel Biochemically and Cellularly Active WRN Inhibitors Derived from a DNA-Encoded Library Screen.
Abbvie
76
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.
Abbvie
34
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement.
Abbvie
6
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Abbvie
1
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Abbvie
9
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
AbbVie
18
Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Abbvie
49
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na
Abbvie
16
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Abbvie
24
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.
Abbvie
11
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.
Abbvie
13
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X
Abbvie
15
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Abbvie
17
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
Abbvie
22
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.
Abbvie
4
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
Abbvie
1
Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.
Abbvie
5
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Abbvie
28
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
Abbvie
25
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Abbvie
32
De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.
Abbvie
24
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.
Abbvie
41
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
Abbvie
48
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Abbvie
32
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Abbvie
24
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.
Abbvie
50
1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS
Abbvie
50
1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
Abbvie
372
APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
Abbvie
100
Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
Abbvie
790
Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
Abbvie
44
Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
Abbvie
619
6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
Abbvie
48
1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS
Abbvie
5
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
5
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
Abbvie
4
The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity.
Abbvie
404
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
187
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
15
Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
Abbvie
346
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
44
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
431
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
Abbvie
404
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
180
Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
Abbvie
15
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abbvie
8
N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
Abbvie